Introduction
============

Otomycosis, a superficial fungal infection of the external auditory meatus, is generally seen in hot and moist climates worldwide and may present as acute, sub-acute, or chronic \[[@b1-jao-2018-00276],[@b2-jao-2018-00276]\]. Factors that predispose patients to otomycosis are the use of wide-spectrum antibiotics, trauma to the external ear canal, and close contact with water \[[@b1-jao-2018-00276]-[@b3-jao-2018-00276]\]. Although a diverse group of microorganisms may be involved in the disease, *Aspergillus* spp. and *Candida* spp. are the microorganisms most commonly isolated from the external ear canal of patients with otomycosis, with *Penicillium* spp., *Mucor* spp., and *Rhizopus* spp. seen less often \[[@b2-jao-2018-00276]-[@b4-jao-2018-00276]\]. Otomycosis usually presents as a superficial infection of the external ear canal skin. However, in cases with perforation of the tympanic membrane, the infection can also affect the middle ear. In rare cases, primarily in immunocompromised individuals, the disease may be extensive and involve the temporal bone \[[@b5-jao-2018-00276]\]. Otomycosis is frequently accompanied by bacterial infections.

Alkalinization of the ear canal and the consequent weakening of its cutaneous barrier produce conditions conducive to mycotic infections. Opportunistic fungal infections of inflamed and desquamated tissues give rise to the accumulation of debris containing hyphae in the external auditory meatus. Depending on the degree of infection, otomycosis may cause itching, pain, or fullness of the ear, as well as hearing loss, discharge, and tinnitus \[[@b2-jao-2018-00276]\].

Multiple topical and oral antifungal agents are widely used in the treatment of otomycosis. Treatment usually requires use of antifungal drops for at least three weeks to prevent recurrence \[[@b6-jao-2018-00276]\]. Eradication of the disease is hard and recurrences as high as 15% can be seen even with appropriate long term topical therapy \[[@b7-jao-2018-00276]\]. Most of the time, patients' unwillingness in applying topical drops routinely for a long period of time, accounts for treatment failures. Therefore, we put in practice a "one-time only" application of an antifungal cream for the treatment of otomycosis and investigated the success of this single visit application. In the present study, we demonstrate that topical treatment applied by filling the external ear canal with 1% clotrimazole cream at a single visit is a cost-effective and efficient treatment modality for otomycosis.

Subjects and Methods
====================

Patients who were referred to the ear, nose, and throat clinics at Harran University School of Medicine Hospital and diagnosed with unilateral otomycosis were enrolled in the study. This study was conducted following approval from the Ethics Committee of the Harran University School of Medicine (74059997.50.01.04/30). The diagnosis of otomycosis was confirmed based on the history of symptoms and otomicroscopic observation of hyphae ([Fig. 1](#f1-jao-2018-00276){ref-type="fig"}). The informed consents of all of the patients were taken.

For each patient, the external ear canal and tympanic membrane were cleaned by aspiration under microscopic examination. Then, the external auditory meatus, beginning at the lateral surface of the tympanic membrane, was filled with 1% clotrimazole cream, using a green IV cannula and an insulin syringe ([Fig. 2](#f2-jao-2018-00276){ref-type="fig"}). The patients received follow-up examinations on days 7, 15, and 45 after cream administration. Wilcoxon test was used to compare the pre-treatment and post-treatment scores for statistical analysis.

Results
=======

Forty patients diagnosed as unilateral otomycosis were enrolled in the study. The mean patient age was 28.6 (21-65) years. There were 22 male and 18 female patients. Thirteen patients had central perforation of the tympanic membrane, two had a radical mastoidectomy cavity, and 25 patients had intact tympanic membranes and external ear canals. All of the patients reported itching of the ear, 14 patients had ear pain, 32 had symptoms of ear fullness and hearing loss, and eight patients presented with tinnitus.

After the treatment, 38 patients had recovered completely from the infection by the end of post-treatment day 7. The remaining two patients denied any symptom regression. Otomicroscopic examinations of the patients who had recovered completely revealed that the external ear canal was totally clean, although some cream remained on parts of the tympanic membrane surface. Pain relief was seen at the end of day 2. Pruritus began to decrease after 5-7 days and had totally resolved by days 10-12. Patients reported that tinnitus and fullness resolved after the external ear canal had been cleaned. Examinations on post-treatment day 15 showed complete resolution of symptoms, and microscopic examinations demonstrated complete eradication of infection and return of the external ear canal to its natural state ([Fig. 3](#f3-jao-2018-00276){ref-type="fig"}). The results of otomicroscopic examinations of the two patients who claimed no symptom relief were the same as the results for the other patients. These two patients complained mainly of a persistent itching sensation.

The distribution of pre-treatment and post-treatment scores of pain, aural fullness and itching of the cases were shown in [Table 1](#t1-jao-2018-00276){ref-type="table"}. According to the statistical analysis, mean average post-treatment scores of the cases for pain, aural fullness and itching were significantly lower than the pre-treatment scores (*p*\<0.01) ([Table 2](#t2-jao-2018-00276){ref-type="table"}, [Fig. 4](#f4-jao-2018-00276){ref-type="fig"}-[](#f5-jao-2018-00276){ref-type="fig"}[6](#f6-jao-2018-00276){ref-type="fig"}).

At 45 days after treatment, 39 of the 40 patients had no complaints. One patient experienced recurrence, which was treated again in the same manner as well as with an oral antifungal medication.

Discussion
==========

Otitis externa is a disease of the external ear canal seen in 5-20% of patients referred to ear, nose, and throat clinics. Although the disease is generally caused by bacteria, fungi may be the factor in 9-25% of cases. A fungal infection of the external ear canal is referred to as fungal otitis or otomycosis. In some cases, bacteria and fungi together may be the cause of infection. Fungal infections frequently occur along with the bacteria *Staphylococcus aureus*, *Pseudomonas* spp., and *Proteus* spp. Interestingly, the fungus *Aspergillus fumigatus* produces an antibiotic against *S. aureus*, so co-infection with these two organisms is not seen \[[@b1-jao-2018-00276]\].

The fungi most commonly isolated from the external ear canal in otomycosis are *Aspergillus* spp. and *Candida* spp. Several studies have reported that *Aspergillus* spp. (*A. niger*, *A. flavus*, *A. fumigatus*) was found in the majority of cases, and *Candida* spp. (*C. albicans*, *C. parapsilosis*, *C. tropicalis*) were seen less frequently \[[@b4-jao-2018-00276],[@b8-jao-2018-00276],[@b9-jao-2018-00276]\].

*Trichosporon* spp. and *Scedosporium* spp. have also been isolated as causes of otomycosis. For example, Reiersöl \[[@b10-jao-2018-00276]\] reported a case of otomycosis caused by *Trichosporon cutaneum*. Two species of *Scedosporium*, a filamentous fungus that lives in water, have been shown to cause otomycosis in humans; these are *S. apiospermum* and *S. prolificans* (*S. inflatum*). An important aspect of *Scedosporium* is its ability to cause severe and often fatal infections in immunocompromised patients \[[@b11-jao-2018-00276],[@b12-jao-2018-00276]\].

Multiple predisposing factors play a role in inducing otomycosis. This infection is seen frequently in regions with tropical climates, where both high humidity and high temperatures occur. Inadequate personal hygiene, close contact of external ear canal with water, and attempts to clean the external ear canal with inappropriate objects also increase the risk for otomycosis, by altering the naturally acidic medium of the external ear canal or through traumatic maceration \[[@b13-jao-2018-00276]\]. In addition, otomycosis is made more likely by the use of multiple and broad-spectrum antibiotics, steroids, or cytostatic medications, as well as the presence of neoplastic diseases or immunocompromised conditions.

Otomycosis affects primarily the squamous epithelium of the external ear canal, causing epithelial damage which results in symptoms of itching, aural fullness, and pain. As in the present study, itching and fullness are foreground symptoms. The external ear canal is edematous and oversensitive. White, black, and brown mycelium deposits can be seen in the external ear canal under otomicroscopic examination. A definitive diagnosis is possible with the culture of fungus in laboratory conditions \[[@b4-jao-2018-00276],[@b14-jao-2018-00276]\].

The first step in the treatment of otomycosis is the elimination of predisposing factors. Then, local cleaning and administration of an antifungal agent (local or systemic) are recommended \[[@b7-jao-2018-00276],[@b13-jao-2018-00276],[@b14-jao-2018-00276]\]. Some studies report that giving ear drops, 3-4 times a day for 5-7 days, to increase the acidity of the ear canal is sufficient to treat the infection, while others suggest daily filling of the ear with an antifungal agent \[[@b15-jao-2018-00276],[@b16-jao-2018-00276]\].

Lucente \[[@b17-jao-2018-00276]\] reported that thimerosal and m-cresyl acetate solutions are effective *in vitro* and that thimerosal is also effective against bacteria other than *Enterococcus*. However, thimerosal should be used for at least 14 days. Vennewald and Klemm \[[@b18-jao-2018-00276]\] concluded that after local cleaning, treatment with a topical antifungal such as clotrimazole, miconazole, bifonazole, cyclopiroxolamine, and tolnaftate is sufficient for noninvasive fungal otitis externa, whereas oral antifungal agents such as itraconazole, voriconazole, and posaconazole, which give better penetration into bone and the nervous system, should be used to treat fungal malignant otitis externa, which can be complicated by meningitis and mastoiditis.

Munguia and Daniel \[[@b19-jao-2018-00276]\] stated that the most effective agents for treating otomycosis are the azole antifungals, followed by nystatin and tolnaftate. In the present study, we administered topical clotrimazole to the patients diagnosed with otomycosis. Clotrimazole is an imidazole derivative with broad-spectrum antimycotic action. Clotrimazole inhibits the biosynthesis of ergosterol, a major component of the cell membranes of yeast and fungi. It replaces the precursor lanosterol as a substrate for the fungal cytochrome P450 enzyme lanosterol-14-demethylase, which catalyzes the conversion of lanosterol to ergosterol. This action alters the permeability of fungal cell walls \[[@b20-jao-2018-00276]\]. In addition to their antimycotic properties, clotrimazole preparations appear to be safe and exhibit no evidence of ototoxicity in guinea pigs \[[@b21-jao-2018-00276]\].

Mofatteh, et al. \[[@b22-jao-2018-00276]\] conducted a study on 204 patients with otoycosis. İn this study compared the recovery rates between topical betadine (povidoneiodine) and clotrimazole. Authors reported the efficacy of betadine and clotrimazole was the same for the treatment of otomycosis.

Romsaithong, et al. \[[@b23-jao-2018-00276]\] conducted a study on 120 otomycosis patients were randomly assigned to receive either 1% clotrimazole solution (intervention group) or 3% boric acid in 70% alcohol (control group). This study reported 1% clotrimazole solution is more effective than 3% boric acid in 70% alcohol for otomycosis treatment.

In our study, we applied 1% clotrimazole cream locally to the external ear canal at a single visit. Such a treatment is more convenient than prescribing topical drops as it does not require patient's compliance or numerous visits for local cleaning. Another similar study is reported by van Hasselt, et al. \[[@b24-jao-2018-00276]\] where they used a single instillation of silver nitrate gel for the treatment of otitis externa. They noted that this kind of a treatment saved both time and cost. Consequently, we believe that filling the external auditory meatus with 1% clotrimazole at a single visit after local cleaning, is a sufficient and cost-effective treatment modality. As antifungal treatments usually need to be administered 3-4 times a day, patient compliance is thought to be poor. With the treatment reported here, compliance would not be an issue.
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###### 

The distribution of pre-treatment and post-treatment scores of pain, aural fullness and itching of the cases

                   Pre-treatment   Post-treatment        
  ---------------- --------------- ---------------- ---- ------
  Pain scores                                            
   0               4               10.0             27   67.5
   1               10              25.0             10   25.0
   2               4               10.0             3    7.5
   3               7               17.5             0    0.0
   4               6               15.0             0    0.0
   5               9               22.5             0    0.0
  Aural fullness                                         
   0               2               5.0              17   42.5
   1               4               10.0             20   50.0
   2               2               5.0              3    7.5
   3               6               15.0             0    0.0
   4               15              37.5             0    0.0
   5               11              27.5             0    0.0
  Itching                                                
   0               0               0.0              17   42.5
   1               0               0.0              17   42.5
   2               0               0.0              6    15.0
   3               4               10.0             0    0.0
   4               10              25.0             0    0.0
   5               26              65.0             0    0.0

###### 

Mean average of pre-treatment and post-treatment scores of pain, aural fullness and itching of the cases

                                    Mean±SD   Median (min-max)   *p*^[\*](#tfn1-jao-2018-00276){ref-type="table-fn"}^
  --------------------------------- --------- ------------------ ------------------------------------------------------
  Pain score (pre-treatment)        2.7±1.7   3 (0-5)            \<0.001
  Pain score (post-treatment)       0.4±0.6   0 (0-2)            
  Aural fullness (pre-treatment)    3.5±1.5   4 (0-5)            \<0.001
  Aural fullness (post-treatment)   0.7±0.8   1 (0-3)            
  Itching (pre-treatment)           4.6±0.7   5 (3-5)            \<0.001
  Itching (post-treatment)          0.7±0.7   1 (0-2)            

Wilcoxon test
